Biostar Pharma to Sell Hepatitis B Treatment in Beijing and Shanghai

Biostar Pharmaceuticals plans to launch its Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai in early January 2010. Xin Aoxing is an OTC treatment for hepatitis B that produced 76% of the company’s revenues in Q3. Biostar said it expects the initiative will add $9 million to 2010 revenues, a meaningful addition to the $48 million of revenues that Biostar is on track to report for 2009. More details... Stock Symbol: (OTCBB: BSPM)